Literature DB >> 19839771

Hip fracture causes excess mortality owing to cardiovascular and infectious disease in institutionalized older people: a prospective 5-year study.

Ian D Cameron1, Jian Sheng Chen, Lyn M March, Judy M Simpson, Robert G Cumming, Markus J Seibel, Philip N Sambrook.   

Abstract

An increasing risk of death after hip fracture has been well documented, but the duration and causes remain unclear, especially in very frail older people. This is a nested case-control study of 229 hip fracture cases and 229 controls matched by age, gender, institution type, and follow-up period from a cohort of 2005 institutionalized older people. The residents were assessed at baseline and followed up for hip fracture and death for at least 5 years. Time to death was measured from the same time for each case (time of the hip fracture) and the matched control. The study sample consisted of 90 males and 368 females with a mean age of 86 years (range 67 to 102 years). The hazard ratio (HR) of death for the cases compared with the controls was 3.09 [95% confidence interval (CI) 1.83-5.22, p < .001] for the first 3 months, 1.99 (95% CI 1.13-3.51, p = .02) for the period of 3 to 9 months, and 0.88 (95% CI 0.64-1.22, p = .46) for the period beyond 9 months following a fracture, after adjusting for age, gender, institution type, weight, immobility, cognitive function, comorbidities, and number of medications. The main causes of the excess mortality in the first 9 months were infections (HR = 6.66, 95% CI 1.95-22.77, p = .002) for females and cardiac disease (HR = 2.68, 95% CI 1.39-5.15, p = .003) for both males and females. Bisphosphonate use was associated with a reduction in mortality after hip fracture (p = .002). Intensive medical supervision to reduce cardiovascular and infective complications should be provided for frail older people with recent hip fracture to reduce mortality. Copyright 2010 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19839771     DOI: 10.1359/jbmr.091029

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  34 in total

1.  Effects of Teriparatide Compared with Risedronate on Recovery After Pertrochanteric Hip Fracture: Results of a Randomized, Active-Controlled, Double-Blind Clinical Trial at 26 Weeks.

Authors:  Per Aspenberg; Jorge Malouf; Umberto Tarantino; Pedro A García-Hernández; Costantino Corradini; Søren Overgaard; Jan J Stepan; Lars Borris; Eric Lespessailles; Frede Frihagen; Kyriakos Papavasiliou; Helmut Petto; José Ramón Caeiro; Fernando Marin
Journal:  J Bone Joint Surg Am       Date:  2016-11-16       Impact factor: 5.284

Review 2.  The definition and clinical significance of nonvertebral fractures.

Authors:  Jacqueline R Center
Journal:  Curr Osteoporos Rep       Date:  2010-12       Impact factor: 5.096

3.  Underdiagnosis and undertreatment of osteoporotic patients admitted in internal medicine wards in Italy between 2010 and 2016 (the REPOSI Register).

Authors:  Jessica Pepe; Pasquale Agosti; Cristiana Cipriani; Mauro Tettamanti; Alessandro Nobili; Luciano Colangelo; Rachele Santori; Mirella Cilli; Salvatore Minisola
Journal:  Endocrine       Date:  2021-01-12       Impact factor: 3.633

4.  Positive Effects of a Sufficient Pre-fracture Serum Vitamin D Level on the Long-Term Survival of Hip Fracture Patients in Finland: A Minimum 11-Year Follow-Up.

Authors:  Ilona Nurmi-Lüthje; Peter Lüthje; Juha-Pekka Kaukonen; Matti Kataja
Journal:  Drugs Aging       Date:  2015-06       Impact factor: 3.923

Review 5.  Public health impact of osteoporosis.

Authors:  Jane A Cauley
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-07-31       Impact factor: 6.053

6.  Excess mortality after pelvic fractures in institutionalized older people.

Authors:  K Rapp; I D Cameron; S Kurrle; J Klenk; A Kleiner; S Heinrich; H-H König; C Becker
Journal:  Osteoporos Int       Date:  2010-01-08       Impact factor: 4.507

Review 7.  Fracture mortality: associations with epidemiology and osteoporosis treatment.

Authors:  Sebastian E Sattui; Kenneth G Saag
Journal:  Nat Rev Endocrinol       Date:  2014-08-05       Impact factor: 43.330

8.  Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study.

Authors:  W Brozek; B Reichardt; J Zwerina; H P Dimai; K Klaushofer; E Zwettler
Journal:  Osteoporos Int       Date:  2015-11-17       Impact factor: 4.507

9.  The discriminatory capacity of BMD measurements by DXA and dual X-ray and laser (DXL) at the calcaneus including clinical risk factors for detecting patients with vertebral fractures.

Authors:  C Muschitz; H P Dimai; R Kocijan; A Kaider; A Zendeli; F Kühne; A Trubrich; S Lung; R Waneck; H Resch
Journal:  Osteoporos Int       Date:  2013-01-24       Impact factor: 4.507

10.  Survival and functional outcomes after hip fracture among nursing home residents.

Authors:  Mark D Neuman; Jeffrey H Silber; Jay S Magaziner; Molly A Passarella; Samir Mehta; Rachel M Werner
Journal:  JAMA Intern Med       Date:  2014-08       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.